Information Provided By: 
Fly News Breaks for July 11, 2017
ALNY, RHHBY, SHPG
Jul 11, 2017 | 13:20 EDT
Cowen analyst Ken Cacciatore believes Shire's (SHPG) current valuation reflects essentially no value for the company's hemophilia franchise. Investors are treating Shire/Baxalta's hemophilia franchise as if it should equate to essentially zero, into perpetuity, beginning in 2020, Cacciatore tells investors in a research note, citing his analysis. He believes this sentiment, based on competitive concerns from Roche (RHHBY) and Alnylam (ALNY), is a "gross overreaction." The analyst has an Outperform rating on Shire with a $325 price target.
News For SHPG;RHHBY;ALNY From the Last 2 Days
RHHBY
Apr 25, 2024 | 11:44 EDT
RHHBY
Apr 24, 2024 | 06:33 EDT
RHHBY
Apr 24, 2024 | 06:30 EDT
ALNY
Apr 23, 2024 | 07:17 EDT
ProQR Therapeutics (PRQR) announced the Annual General Meeting, AGM, of Shareholders will take place on Wednesday, May 22, 2024 at the offices of Allen & Overy LLP, in Amsterdam, the Netherlands. As part of the AGM, Martin Maier, PhD, is nominated for appointment as a non-executive Board Member for a period of four years. Dr. Maier is Senior Vice President Research heading the Oncology group at Alnylam Pharmaceuticals (ALNY).
